Clinical Research Directory

Inclusion Criteria: * Measurable disease at baseline per RECIST v1.1 * ECOG performance status of 0 or 1 * Adequate organ function * Metastatic NSCLC: * Must have histologically confirmed metastatic NSCLC. * Tumor must have been assessed for EGFR and ALK per local standard of practice; patients with these driver mutations are excluded. * Patients with tumors known to have the following alterations are excluded: ROS1, RET, MET, HER-2, NTRK 1/2/3. * Patients must have previously derived clinical benefit from a PD-1/PD-L1 inhibitor or PD-1/PDL-1 bispecific without progression for at least 6 months. Exclusion Criteria: * Prior treatment with IL-2 * History of significant pulmonary disease * History of clinically significant cardiovascular disease * Active CNS metastases * Pregnant or breastfeeding In Phase 1, participants with select additional solid tumor types may be enrolled.